← Peptide hub
Tracker
Peptide Regulatory Tracker
Current legal status for every peptide we cover, the date we last verified it, and what that status actually means. We update this the moment the record changes, not on a fixed schedule.
Every row below independently verified 2026-07-31.
Educational information only, not medical advice. A favorable status here is not a safety or efficacy finding; see each peptide's own page for the evidence. Talk to a physician before making any decision about a prescription medication or an unregulated substance.
PCAC-recommended, not yet legal
Verified2026-07-31
FDA reviewed forUlcerative colitis (PCAC review, 23 Jul 2026)
What this means for youAn FDA advisory committee recommended this for compounding, but the recommendation is non-binding and nothing has changed legally. Not a legal source for human use today.
Research-use-only, no legal human-use pathway
Verified2026-07-31
FDA reviewed forOpioid withdrawal, chronic insomnia, and narcolepsy (PCAC review, 24 Jul 2026; rejected)
What this means for youNo legal path to human use exists. Sold only as an unregulated research chemical, not for human consumption.
PCAC-recommended, not yet legal
Verified2026-07-31
FDA reviewed forWound healing and inflammatory conditions (PCAC review, 23 Jul 2026)
What this means for youAn FDA advisory committee recommended this for compounding, but the recommendation is non-binding and nothing has changed legally. Not a legal source for human use today.
PCAC-recommended, not yet legal
Verified2026-07-31
FDA reviewed forObesity and osteoporosis (PCAC review, 23 Jul 2026)
What this means for youAn FDA advisory committee recommended this for compounding, but the recommendation is non-binding and nothing has changed legally. Not a legal source for human use today.
FDA-approved
Verified2026-07-31
FDA reviewed forHypoactive sexual desire disorder (HSDD) in premenopausal women (Vyleesi)
What this means for youLegal by prescription, dispensed through a licensed pharmacy, for the specific approved use only. Using it for anything else is off-label and not covered by this approval.
FDA-approved
Verified2026-07-31
FDA reviewed forType 2 diabetes (Ozempic) and chronic weight management (Wegovy), each a separately approved indication
What this means for youLegal by prescription, dispensed through a licensed pharmacy, for the specific approved use only. Using it for anything else is off-label and not covered by this approval.
PCAC-recommended, not yet legal
Verified2026-07-31
FDA reviewed forCerebral ischemia, migraine, and trigeminal neuralgia (PCAC review, 24 Jul 2026)
What this means for youAn FDA advisory committee recommended this for compounding, but the recommendation is non-binding and nothing has changed legally. Not a legal source for human use today.
PCAC-recommended, not yet legal
Verified2026-07-31
FDA reviewed forWound healing (PCAC review, 23 Jul 2026)
What this means for youAn FDA advisory committee recommended this for compounding, but the recommendation is non-binding and nothing has changed legally. Not a legal source for human use today.
FDA-approved
Verified2026-07-31
FDA reviewed forReduction of excess abdominal fat in adults with HIV-associated lipodystrophy (Egrifta)
What this means for youLegal by prescription, dispensed through a licensed pharmacy, for the specific approved use only. Using it for anything else is off-label and not covered by this approval.
FDA-approved
Verified2026-07-31
FDA reviewed forType 2 diabetes (Mounjaro) and chronic weight management (Zepbound), each a separately approved indication
What this means for youLegal by prescription, dispensed through a licensed pharmacy, for the specific approved use only. Using it for anything else is off-label and not covered by this approval.
| Peptide ▾ | Regulatory status ▾ | Verified ▾ | FDA reviewed for ▾ | What this means for you |
|---|---|---|---|---|
| BPC-157 | PCAC-recommended, not yet legal | 2026-07-31 | Ulcerative colitis (PCAC review, 23 Jul 2026) | An FDA advisory committee recommended this for compounding, but the recommendation is non-binding and nothing has changed legally. Not a legal source for human use today. |
| DSIP | Research-use-only, no legal human-use pathway | 2026-07-31 | Opioid withdrawal, chronic insomnia, and narcolepsy (PCAC review, 24 Jul 2026; rejected) | No legal path to human use exists. Sold only as an unregulated research chemical, not for human consumption. |
| KPV | PCAC-recommended, not yet legal | 2026-07-31 | Wound healing and inflammatory conditions (PCAC review, 23 Jul 2026) | An FDA advisory committee recommended this for compounding, but the recommendation is non-binding and nothing has changed legally. Not a legal source for human use today. |
| MOTS-c | PCAC-recommended, not yet legal | 2026-07-31 | Obesity and osteoporosis (PCAC review, 23 Jul 2026) | An FDA advisory committee recommended this for compounding, but the recommendation is non-binding and nothing has changed legally. Not a legal source for human use today. |
| PT-141 / Bremelanotide | FDA-approved | 2026-07-31 | Hypoactive sexual desire disorder (HSDD) in premenopausal women (Vyleesi) | Legal by prescription, dispensed through a licensed pharmacy, for the specific approved use only. Using it for anything else is off-label and not covered by this approval. |
| Semaglutide | FDA-approved | 2026-07-31 | Type 2 diabetes (Ozempic) and chronic weight management (Wegovy), each a separately approved indication | Legal by prescription, dispensed through a licensed pharmacy, for the specific approved use only. Using it for anything else is off-label and not covered by this approval. |
| Semax | PCAC-recommended, not yet legal | 2026-07-31 | Cerebral ischemia, migraine, and trigeminal neuralgia (PCAC review, 24 Jul 2026) | An FDA advisory committee recommended this for compounding, but the recommendation is non-binding and nothing has changed legally. Not a legal source for human use today. |
| TB-500 | PCAC-recommended, not yet legal | 2026-07-31 | Wound healing (PCAC review, 23 Jul 2026) | An FDA advisory committee recommended this for compounding, but the recommendation is non-binding and nothing has changed legally. Not a legal source for human use today. |
| Tesamorelin | FDA-approved | 2026-07-31 | Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy (Egrifta) | Legal by prescription, dispensed through a licensed pharmacy, for the specific approved use only. Using it for anything else is off-label and not covered by this approval. |
| Tirzepatide | FDA-approved | 2026-07-31 | Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), each a separately approved indication | Legal by prescription, dispensed through a licensed pharmacy, for the specific approved use only. Using it for anything else is off-label and not covered by this approval. |
Epitalon is not yet listed: its human-trial citations could not be independently verified in this research pass, so it is held pending sourcing rather than published unverified.